28 April 2014 - Sequana Medical raises $26m after relocating from California to Zug in Switerland.
Sequana raised the investment in a financing round led by Life Sciences Partners, a European private equity fund (Germany, The Netherlands).
Source :
- Financial Times
http://www.ft.com/cms/s/0/afbd51e8-cc79-11e3-bd33-00144feabdc0.html#axzz30DLBh8zz
- Sequana news
About Life Sciences Partners
In April 2011, LSP launched its LSP Life Sciences Fund on Euronext.
This fund is open-ended and publicly listed. As such, it allows
investors to buy shares of the fund at any time, via their (internet)
broker. The fund’s Bloomberg ticker is LSP NA and its ISIN Code is
NL0009756394.
Novadip Biosciences
BRUSSELS (Reuters) - January 2014 - Belgian medical researchers have succeeded in repairing bones using stem cells from fatty tissue, with a new technique they believe could become a benchmark for treating a range of bone disorders.
The team at the Saint Luc university clinic hospital in Brussels have treated 11 patients, eight of them children, with fractures or bone defects that their bodies could not repair, and a spin-off is seeking investors to commercialize the discovery.
The team at the Saint Luc university clinic hospital in Brussels have treated 11 patients, eight of them children, with fractures or bone defects that their bodies could not repair, and a spin-off is seeking investors to commercialize the discovery.
G8 dementia summit London
London - 13 December 2013 - The UK is hosting a G8 summit on dementia in London on 11 December. The
summit aims to develop co-ordinated global action on dementia.
see G8-dementia-summit
see G8-dementia-summit
Janssen-Deloitte Investing in European Health R&D
Brussels, 7 October 2013: A report published today shows that European research and development (R&D) investments in health have stagnated since 2010, and this is the first time after decades of annual increases. The report was commissioned by Janssen Pharmaceutica NV and the research was conducted by Deloitte Health Economics group.
- The report-“Investing in European Health R&D"
- Presentation slides Jane Griffiths
- Investing in European health R&D – Press Release 7 October 2013
- Backgrounder on Janssen research initiatives and collaboration
- Report Executive Summary - Investing in European health R&D
- Graph: R&D Distribution and intensity by sector in the European Union
- Graph: Total health-related R&D in Europe in 2011
- Graph: Private (2011) and Public (2010) health-related R&D expenditures per country
- Graph: Evolution total health-related R&D 2004-2011 in EU and US
Source : Janssen health policy centre
Skolkovo Innovation Center: Russia investing $4 Billion in ‘innovation city’ Skolkovo to insemminate startup culture
9 August 2013
The Russian government is spending billions of dollars to manufacture startup culture.
Skolkovo is a science park outside of Moscow that aims to be the “Russian Silicon Valley.” It is the country’s largest state-sponsored innovation hub, and it will receive around $4 billion in state funding between now and 2020.
Skolkovo Foundation president Viktor Vekselberg said he expects to raise more than $11 billion in private investment by 2020 and that Skolkovo will not need government financing after 2025. He also predicted that this “innovation city” will contribute $6.5 billion to Russia’s economy over that time
The Russian government is spending billions of dollars to manufacture startup culture.
Skolkovo is a science park outside of Moscow that aims to be the “Russian Silicon Valley.” It is the country’s largest state-sponsored innovation hub, and it will receive around $4 billion in state funding between now and 2020.
Skolkovo Foundation president Viktor Vekselberg said he expects to raise more than $11 billion in private investment by 2020 and that Skolkovo will not need government financing after 2025. He also predicted that this “innovation city” will contribute $6.5 billion to Russia’s economy over that time
Bill & Melinda Gates Foundation: New partnership to fight poverty-related diseases
10 June 2013 -
The European Union and the Bill & Melinda Gates Foundation have today pledged to work together to fight HIV/AIDS, tuberculosis, malaria and other poverty-related diseases that together affect more than 1 billion people worldwide. The agreement, signed in Paris today by foundation co-chair Bill Gates and European Commissioner for Research, Innovation and Science, Máire Geoghegan-Quinn, creates a new strategic partnership for research in the area. Between 2007 and 2011, the foundation and the European Commission have contributed around 2.4 billion euro (3.1 billion USD) to research and development focused on poverty-related infectious diseases, supporting the development of more than 20 new and improved products.
The European Union and the Bill & Melinda Gates Foundation have today pledged to work together to fight HIV/AIDS, tuberculosis, malaria and other poverty-related diseases that together affect more than 1 billion people worldwide. The agreement, signed in Paris today by foundation co-chair Bill Gates and European Commissioner for Research, Innovation and Science, Máire Geoghegan-Quinn, creates a new strategic partnership for research in the area. Between 2007 and 2011, the foundation and the European Commission have contributed around 2.4 billion euro (3.1 billion USD) to research and development focused on poverty-related infectious diseases, supporting the development of more than 20 new and improved products.
The partnership will invest in research and development of life-saving interventions to improve the health and well-being of people living in developing countries. In addition to accelerating the development of much-needed drugs, vaccines and diagnostics, the two organisations will also seek to improve affordable and sustainable pathways to ensure that these products quickly reach those in greatest need.
More information:
Google Ventures is funding 8 healthcare and life sciences companies
April 2013 -
Google Ventures has been backing startups through its venture capital fund since 2009 and offers a pretty diverse range of services to entrepreneurs. It has eight healthcare and life science businesses among its portfolio companies spanning innovative areas such as DNA analysis, accelerated drug development, and oncology analytics.
Google Ventures has been backing startups through its venture capital fund since 2009 and offers a pretty diverse range of services to entrepreneurs. It has eight healthcare and life science businesses among its portfolio companies spanning innovative areas such as DNA analysis, accelerated drug development, and oncology analytics.
Actavis Watson Pharmaceuticals acquiert la société liégeoise Uteron Pharma pour 305 millions de dollars
January 2013
Actavis, New Jersey, (anciennement Watson Pharmaceuticals) a racheté Uteron
Pharma, société biopharmaceutique liégeoise, pour un montant de USD 150 million cash et USD 155 millions par versements d’étapes (potential future milestone payments).
Uteron Pharma, dont le personnel s’élève à 60 personnes, est une spin-off spécialisée dans la contraception et la fertilité, la ménopause et l’ostéoporose, les infections vaginales et les cancers féminins.
Uteron Pharma, dont le personnel s’élève à 60 personnes, est une spin-off spécialisée dans la contraception et la fertilité, la ménopause et l’ostéoporose, les infections vaginales et les cancers féminins.
Par ailleurs, cette
collaboration devrait permettre de poursuivre des projets de recherche
ainsi que le lancement sur le marché de produits demandant des
investissements importants, estime le CEO d’Uteron Pharma, Stijn Van
Rompay, qui souligne que le personnel ne sera pas affecté par ce rachat.
Source: RTL.be, Express.be, Actavis, Uteron
Uteron Pharma SA, Rue Saint Georges 5, B- 4000 Liège
Uteron Pharma SA, Rue Saint Georges 5, B- 4000 Liège
TiGenix to Raise Capital via a Private Placement of New Ordinary Shares
19 December 2012 - Leuven, Belgium – TiGenix NV (Euronext Brussels: TIG) today announced that it will launch a private placement of up to 8,629,385 new ordinary shares.
TiGenix will use the funds mainly for the commercial roll out of ChondroCelect in selected European markets and for progressing with the clinical development of Cx601 in complex perianal fistulas in Crohn's patients.The new shares will be placed through an accelerated bookbuilding procedure. The placing will start on 19 December 2012. The Company has asked the Financial Services and Markets Authority (FSMA) to suspend its shares from trading on NYSE Euronext Brussels. Trading in the share will resume shortly following the publication of the results of the placing.
The Company will announce the results of the placing as soon as possible after closing of the bookbuilding.
Source : tigenix.com
Une app smartphone mesure votre état de santé en temps réel
17 Décembre 2012 - Une apps smartphone révolutionne le monde médical.
Une révélation pour tous les hypocondriaques ou autres soucieux de leur santé qui grâce à cette nouvelle application pourront contrôler à la fois leur fréquence cardiaque, poids, pression artérielle, ou encore de surveiller taux de cholestérol et de glycémie.
Examiner sa santé au quotidien ne sera plus l'affaire des généralistes ou des médecins spécialisés, mais l'opportunité de tout un chacun. Cette application a été accueillie comme la médecine préventive du futur.
Source : siliconwadi.fr
http://siliconwadi.fr/5890/une-application-smartphone-mesure-votre-etat-de-sante-en-temps-reelle
Une révélation pour tous les hypocondriaques ou autres soucieux de leur santé qui grâce à cette nouvelle application pourront contrôler à la fois leur fréquence cardiaque, poids, pression artérielle, ou encore de surveiller taux de cholestérol et de glycémie.
Examiner sa santé au quotidien ne sera plus l'affaire des généralistes ou des médecins spécialisés, mais l'opportunité de tout un chacun. Cette application a été accueillie comme la médecine préventive du futur.
Source : siliconwadi.fr
http://siliconwadi.fr/5890/une-application-smartphone-mesure-votre-etat-de-sante-en-temps-reelle
TiGenix Reacts to Rumors
Leuven, Belgium – 14 December 2012
TiGenix NV (Euronext Brussels: TIG) announces that, apparently as a result of unauthorized access to certain non-public sections of TiGenix’s website, draft announcements regarding a potential capital increase by way of a private placement have surfaced today on certain internet forums.
As is common in the biotech sector, the company regularly examines and prepares for opportunities to secure additional financing, including the possibility of a capital increase.
However, TiGenix has not taken a decision to engage in such a transaction at this point in time. If and when such a transaction were to be decided, the company will inform the market in due course.
More info : Tigenix.com
TiGenix NV (Euronext Brussels: TIG) announces that, apparently as a result of unauthorized access to certain non-public sections of TiGenix’s website, draft announcements regarding a potential capital increase by way of a private placement have surfaced today on certain internet forums.
As is common in the biotech sector, the company regularly examines and prepares for opportunities to secure additional financing, including the possibility of a capital increase.
However, TiGenix has not taken a decision to engage in such a transaction at this point in time. If and when such a transaction were to be decided, the company will inform the market in due course.
More info : Tigenix.com
Euroscreen raises €10 million in Equity Investments led by Vesalius BioCapital
Brussels, Belgium, November 30, 2012 –
Euroscreen, a drug development company focused on the development of novel GPCR drug concepts including next generation sex hormone control in woman’s health announced today that it has completed a €10 million Series A preferred stock financing led by Vesalius Biocapital II Partners and SRIW (Société Régionale d’Investissement de Wallonie SA).
The proceeds of the round will mainly be used to develop its main advanced product ESN364 for the treatment of endometriosis, a disease that affects 6-10% of women in childbearing age.
"We have been delighted to work with Vesalius and SRIW, and other new shareholders as LSRP (Life Sciences Research Partners VZW); SPDG (Société de Participation et de Gestion SA) and Hunza Ventures, in addition to our existing shareholders, to maximize Euroscreen’s potential to advance our lead program, ESN364 into clinical development.
Jean Combalbert, Euroscreen's CEO said "We thank those existing shareholders participating in this new financing round which included Fortis Private Equity, Compagnie du Bois Sauvage SA, Ackermans & Van Haaren NV, our university-based shareholders and some of our individual faithful shareholders”.
Galapagos discovers novel class of antibiotics
26 November 2012 - Belgium
First candidate antibiotic is effective against all tested MRSA strains
- May offer treatment against multiple drug-resistant infections
- Proprietary to Galapagos, based on novel target DNA pol III alpha (DnaE)
- Clinical development of first antibiotic initiated
UCB and NewBridge Pharmaceuticals Partner for Middle East and African markets
Brussels, Belgium and Dubai, November 21, 2012 - UCB (Euronext Brussels: UCB) and NewBridge Pharmaceuticals, today announced an exclusive partnership agreement to make UCB's core products Cimzia®, Vimpat® and Neupro® available in several Middle East and African countries. Under the agreement, NewBridge acquires the rights to Cimzia®, Vimpat® and Neupro® from the RX Group, UCB's previous partner in the region. UCB will now operate with its new partner for the region and will supply NewBridge with the three products on exclusive basis. NewBridge will also be responsible for managing the local regulatory approval process, future commercialization, and pharmacovigilance in each of the relevant countries.
NewBridge Pharmaceuticals (NBP) is a first-in-class, venture-backed specialty therapeutics company focused on pharmaceuticals, biologics. NBP specializes in in-licensing, acquiring, registering and commercializing FDA, EMA/European and Japanese PMDA approved therapeutics to address the unmet medical needs of diseases with high regional prevalence in the Middle East, Africa, Turkey regions.
Headquartered in Dubai, NBP has investment support from Burrill & Company (Burrill), a San Francisco-based global leader in life sciences with activities in venture capital, private equity, merchant banking and media, and the life science arm of National Technology Enterprises Company (NTEC), a Kuwait investment authority mandated fund operating out of Kuwait City. The Burrill/NTEC expansive life sciences network and partnership support provides NBP unprecedented access to U.S., European and Japanese biotechnology companies, products and investment expertise.
Kuwait Life Sciences Company (KLSC) is a wholly owned company of National Technology Enterprises Company (NTEC), capitalized at USD 16.5 million, to act as its regional investment arm in healthcare and life sciences space. In turn, NTEC is fully owned by Kuwait Investment Authority (KIA) and was established in 2004 to act as a 'corporate venture capitalist' focused on international technology investments and be the gateway for sustainable transfer of emerging technologies to Kuwait and the Middle East region. NETC is uniquely positioned as a technology investor in the region and enjoys a broad network with venture capital funds, investment companies, industry leaders, research centers and governmental bodies. KLSC aims to create start up projects, invest in growing companies which exhibit novelty, possess a technological edge, have a sustainable business model, fulfill a compelling need or offer significant value to healthcare sector in Kuwait and Middle East.
NewBridge Pharmaceuticals (NBP) is a first-in-class, venture-backed specialty therapeutics company focused on pharmaceuticals, biologics. NBP specializes in in-licensing, acquiring, registering and commercializing FDA, EMA/European and Japanese PMDA approved therapeutics to address the unmet medical needs of diseases with high regional prevalence in the Middle East, Africa, Turkey regions.
Headquartered in Dubai, NBP has investment support from Burrill & Company (Burrill), a San Francisco-based global leader in life sciences with activities in venture capital, private equity, merchant banking and media, and the life science arm of National Technology Enterprises Company (NTEC), a Kuwait investment authority mandated fund operating out of Kuwait City. The Burrill/NTEC expansive life sciences network and partnership support provides NBP unprecedented access to U.S., European and Japanese biotechnology companies, products and investment expertise.
Kuwait Life Sciences Company (KLSC) is a wholly owned company of National Technology Enterprises Company (NTEC), capitalized at USD 16.5 million, to act as its regional investment arm in healthcare and life sciences space. In turn, NTEC is fully owned by Kuwait Investment Authority (KIA) and was established in 2004 to act as a 'corporate venture capitalist' focused on international technology investments and be the gateway for sustainable transfer of emerging technologies to Kuwait and the Middle East region. NETC is uniquely positioned as a technology investor in the region and enjoys a broad network with venture capital funds, investment companies, industry leaders, research centers and governmental bodies. KLSC aims to create start up projects, invest in growing companies which exhibit novelty, possess a technological edge, have a sustainable business model, fulfill a compelling need or offer significant value to healthcare sector in Kuwait and Middle East.
Neurotech, Louvain-La-Neuve, acquired by SORIN, Milano
ThromboGenics announces Business Update Q3 2012
8 November 2012 -
ThromboGenics (Heverlee, Belgium) announces Business Update Q3 - The Company reported revenues of 75.1 million EUR in the first nine months of 2012 versus €2.5 million in the first nine months of 2011. The revenues in 2012 are almost entirely due to the upfront payment from Alcon.
In March, ThromboGenics raised 77.8 million EUR in a private placement
Thrombogenics.com
Thrombogenics.com
Marleen Temmerman becomes Director at WHO
October 2012 -
Professor Marleen Temmerman , is a Belgian national who qualified as a medical doctor from Ghent University. She also holds a diploma in tropical medicine from the Institute of Tropical Medicine, Antwerp; an MPh on epidemiological, statistical and operational methods applied in public health; a PhD in obstetrics and gynaecology; and a diploma in management.
She is also a Belgian politician and a member of the Socialistische Partij .
Professor Marleen Temmerman , is a Belgian national who qualified as a medical doctor from Ghent University. She also holds a diploma in tropical medicine from the Institute of Tropical Medicine, Antwerp; an MPh on epidemiological, statistical and operational methods applied in public health; a PhD in obstetrics and gynaecology; and a diploma in management.
She is also a Belgian politician and a member of the Socialistische Partij .
Janssen Pharmaceutica ouvre un nouveau Centre Européen de Distribution à la Louvière.
La Louvière, le 3 octobre 2012 – Janssen Pharmaceutica investit 49 millions euros dans ce nouveau centre qui offre une opportunité d’emploi à 115 personnes. Janssen inaugure ce 3 octobre 2012 son nouveau Centre européen de Distribution de produits pharmaceutiques à La Louvière. Le centre fait partie du réseau de distribution du groupe mondial Johnson & Johnson et servira de plaque tournante pour la distribution de médicaments innovants de Janssen vers les patients dans
l’Europe tout entière. Le Centre européen de Distribution centralise les activités de 15 plateformes logistiques. De ce fait, les produits pharmaceutiques provenant des différents sites de production européens sont acheminés vers un unique centre de distribution. Les produits sont envoyés depuis ce centre vers les entreprises Janssen dans 11 pays européens et les filiales Johnson & Johnson dans le monde entier.
« Le Centre européen de Distribution de La Louvière nous permet de livrer nos produits pharmaceutiques, qui répondent à de réels besoins de la part des patients, de manière plus efficace. Les hôpitaux verront également diminuer le poids de leur logistique et de leurs coûts administratifs grâce à cette nouvelle structure », déclare Tom Heyman, CEO de Janssen Pharmaceutica. « En outre, la direction des trois centres de distribution en Belgique (Beerse, Courcelles et La Louvière) sera centralisée. La très grande proximité de ces trois Centres européens de Distribution permet de tirer parti de synergies et d’échanger les meilleures pratiques et le know how».
Senior Nurse Administrator CHIREC for Kuwait Hospital
October 2012 - Senior Nurse Administrator CHIREC - >Kuwait Hospital
Description de l'entreprise: Job offer in Kuwait hospital. Looking for m/f Senior Nurse Administrator Interested? Please send your cv to the Centre Hospitalier Interrégional Edith Cavell For the attention of Mrs Cambier, director of the Chirec’s nursing department • by e-mail : isabelle.cambier@chirec.be • by post : 8-10 rue Jules Cockx, 1160 Auderghem.
Le BLSI recrute un CEO -
2012 - Bruxelles
______________________________________________________
Brussels Life Science Incubator (« BLSI »)
Le BLSI recrute un CEO - source : www.vivesfund.com
______________________________________________________
______________________________________________________
Brussels Life Science Incubator (« BLSI »)
Le BLSI recrute un CEO - source : www.vivesfund.com
______________________________________________________
Subscribe to:
Posts (Atom)